We've sold about 170 units over the last 16 months and I'm impressed by the number of people who are reporting rather quick positive response to using the new model Neuradiant 1070 4Q transcranial photobiomodulation system. The most common response has been improved sleep and decreased brain fog which has been among the top 5 most often reported areas of change from previous users of the 1070nm stimulation. We've had 3 returns of the total number sold which is a testament to the value folks are seeing in using this technology.
Clinicians like Rick Abbey, Ph.D a neuropsychologist in Palo Alto have noted on social media and in personal discussions that his clients are regularly reporting positive responses to using the Neuradiant units in their efforts to overcome a wide range of cognitive, behavioral and learning-based challenges. The team at Neuronic are noting testimonials appearing on on Trust Pilot acknowledging the ease of use and rapid changes in functioning among users of the new 1070 4Q system. I've even been called by family members who used the unit on their loved ones to report remarkable almost immediate changes in focus and attention and verbal behavior who were in very advanced stages of dementia. This is not all that unusual if you think about neurodegeneration as a failing battery's ability to hold a charge. So, if you infuse the battery with a strong charge using high levels of concentrated sunlight, you reinvigorate it's ability to drive activities that required more 'juice' than it could previously deliver. The more often you boost the battery (brain tissue) with this type of charge, the more flexible and capable it becomes at holding the charge for longer periods of time. If you then add neurofeedback training to the protocol you are then upgrading the wiring system that supports the transmission of the power to all the other systems in the body with a corresponding overall functional improvement in cognition,, movement, and self expression. Our work now is on integrating these functions more efficiently wherein we'll drive the stimulation based on changes in the overall central nervous system's functional efficiency. We're getting there.
0 Comments
COVID ups risks of dementia, cognitive impairment, and decline in older survivorsSadly and not surprisingly, the science media is reporting that the neurological impact of covid 19 is showing increased levels of cognitive decline worldwide. Older adults are having to cope with damage to their lungs and central nervous system. The study noted that the telephone survey measures used were limited in identifying more specific challenges and likely underestimate the size of the problem due to having excluded subjects with any family history of dementia. The global dementia care burden is likely to be greater as a result of the COVID-19 pandemic and so there is even greater need to rapid intervention now that can be easily, safely and cost effectively deployed. Researchers and clinicians at Quietmind Foundation, Neuronic Devices Ltd (Neuronic.online), Baylor Research Institute and the Biophotonic and Neuroimaging Lab•UTexas-Arlington are collaborating to show the effectiveness of self-administered, transcranial infrared light-based therapy to reduce dementia's cognitive and behavioral symptoms.
The Neuradiant 1070 4Q technology that's being released this month by Neuronic Devices Ltd. (see Neuronic.online) is a resource that can address the debilitating impact of COVID 19 on the brain by increasing cortical perfusion and ATP production by stimulating cytochrome c oxidase and improving blood vessel flexibility. In addition, the new independent 4 -quadrant control of pulse frequency allows for renormalization of dysregulated brain network connectivity using the light pulsations to directly changes in EEG activity. https://arstechnica.com/science/2022/03/covid-ups-risks-of-dementia-cognitive-impairment-and-decline-in-older-survivors/ Mental disorders in early life are associated with a significantly increased risk of dementia in later years.
|
1pbm_depression_anxiety_and_cognition.pdf | |
File Size: | 420 kb |
File Type: |

pbm_-_normal_people.pdf | |
File Size: | 178 kb |
File Type: |
Devices based on these findings are now available under clinical supervision through Quietmind Foundation. Inquiries should be directed to Marvin Berman PhD 610-940-0488
Read the UVA article here.
________________________________________
From Annie,
I started using the Vielight Neuro Gamma PBM helmet on 4/16/2021. At that time, I was experiencing severe pain and leg weakness from an auto-immune neurological disorder, significant irritable bowel syndrome manifested by chronic constipation (IBS-C), recurrent chest pain due to a lung infection, excessive fatigue and depression. My auto-immune disorder and related medical issues problems had been steadily worsening since May 2019. By April 2021 I had trouble climbing more than three steps, walking more than a city block, carrying out simple house work or grocery shopping and chronic pain that averaged 5-8 daily (on a scale of 1 – 10).
My symptoms also interfered with memory and concentration.
I initially started using the Vielight as an alternative to increasingly powerful opioid pain killers. I tried the gamma stimulation for a 30 second interval once a day. I found the stimulation disruptive (it increased my irritability and depressed my mood). I then tried the alpha stimulation for 30 seconds, and slowly increased by 30 seconds to 5 minutes once a day. In June, after 2 months, I went to twice a day (morning and early evening) alpha stimulation with 5 minute durations.
I noticed that the severe neuropathic pain (burning, tingling in my legs and arms) as well as the severe joint pain in my knees, hands, wrists, and hips slowly decreased after about a month of daily use. I also noticed that my pain level would shoot back up if I skipped a day, and was excruciating if I skipped two days. I have discontinued strong pain killers and now only need an occasional Tylenol. In addition, my mood stabilized and markedly improved after 3 months of twice daily use. I use the Vielight while watching TV or reading the paper.
Prior to using the Vielight, I reached a point where I could not stand for more than 15 minutes or carry groceries over 5 pounds. I had to take stimulant medication in order to get out of bed. If I didn't take the medication, I needed daily hour-long naps in the mid-afternoon and didn’t have the energy to do anything. At times over the past two years, I have needed to use a cane or walker to be able to get around in my own home and couldn't walk more than 1/2 city block. Now, I can stand for several hours, easily ascend and descend two flights of stairs, and recently walked over 3,000 steps.
I had two episodes of severe colitis over the past year (one requiring hospitalization) and was taking prescription strength medication to address chronic constipation. In mid-September I started to taper the medication and as of October, no longer have a problem with constipation and have discontinued this medication. My strength has improved to a point that in early September I was able to resume food shopping, cooking, and light housework.
In early October 2021, (after 6 months of use) I started added 2 minutes of gamma stimulation followed by 5 minutes of alpha once a day in the morning, and a separate 5 minute session of alpha stim. in the afternoon. I will slowly increase the length of gamma stimulation. I immediately notice improved mental clarity. (For example, on 10/5 I suggested to my daughter’s NP that they check my daughter’s hormone blood levels and consider using Botox injections for pelvic pain).
Lastly, no more suicidal ideation.
Call 267-481-3987 for more information or write MarvinBerman@quietmindfdn.org
A Florida trial court has denied a defendant’s Daubert motion to strike the plaintiff’s expert’s testimony regarding qEEG testing. In Snyder v. ESURANCE Property and Casualty Insurance Company, Case No. 01-2018-CA-2651 (8th Judicial Circ. Ala. Chua. Cty., FL), the defendant sought to bar the testimony of Dr. Lisa Avery, an eligible board neurologist, from testifying regarding her interpretation of a quantitative electroencephalogram (qEEG). To support its motion, the defendant submitted “only” three articles and argued at a hearing that using qEEG for diagnosing mild traumatic brain injury had been prohibited by the American Academy of Neurology (AAN) for over 20 years. Noteworthy in the court’s opinion was that the AAN guideline relied upon by the defense was “retired” in January 2020 and was no longer the official position of the Academy.
The defendant presented two expert witnesses: Dr. Mary Schriver, a board- certified neurologist with a sub-specialty in neurophysiology, and Dr. Jason Demery, a board-certified neuropsychologist. While Dr. Schriver testified that she did not believe qEEG was a valid test for the diagnosis of traumatic brain injury, she did acknowledge that other doctors did use the test for that purpose. During the cross-examination, the plaintiff demonstrated that Dr. Schriver was unfamiliar with the software utilized by Dr. Avery, who was not an expert in interpreting it, and did not examine the raw data generated by the qEEG.
Dr. Demery also admitted that he was not qualified to administer or utilize a qEEG, nor was he an expert in qEEG in general. Dr. Demery disputed some findings in the numerous peer reviewed articles submitted by the plaintiff and raised false positives due to sleep apnea or medication, but did not produce, cite or reference any additional peer reviewed articles to support his position.
Contrasting the defendant’s presentation, the plaintiff submitted numerous peer-reviewed articles comprising over 140 pages, including book chapters and scientific journals supporting the use of qEEG in TBI diagnosis. The peer-review literature produced by the plaintiff denied the error rate argument supported by the defendant and established the wide-spread use of qEEG in diagnosing traumatic brain injury throughout the VA Hospital system. The plaintiff’s experts, Dr. Avery and Dr. Richard Boehme, M.D., testified that they used qEEG in their everyday practices and were familiar with the literature and its use. Due to their clinical experience, the court found the plaintiff’s witnesses to be persuasive.
After the court conducted a Daubert analysis, they found Dr. Avery was qualified, her testimony was based upon sufficient facts and data, and that utilizing qEEG as a tool to help diagnose traumatic brain injury was sufficiently reliable, scientific, and valid. The court also found that Dr. Avery reliably applied the qEEG to the specific case before it.
The court found that the case law presented by the defendant was not controlling as the cases cited were decided before the retirement of the AAN position and most were decided under a Frye standard. Based on the evidence offered at two hearings, the court concluded that qEEG testing related to traumatic brain injury was reliable and scientific when used with other tests or data, rejecting and denying defendant’s motion to strike.
QMF News
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.
Archives
March 2022
November 2021
October 2021
September 2021
August 2021
July 2021
June 2021
May 2021
April 2021
February 2021
January 2021
December 2020
November 2020
October 2020
September 2020
August 2020
July 2020
June 2020
May 2020
April 2020
March 2020
February 2020
January 2020
December 2019
October 2019
September 2019
August 2019
June 2019
May 2019
April 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
April 2018
March 2018
November 2017
October 2017
September 2017
August 2017
July 2017
May 2017
Categories
All
Alzheimer's
Biofeedback
Breathing Training
Dementia
Dementia Treatment
Drug Free Anxiety Treatment
Infrared Light
Light Therapy
Neurofeedback
Neurotherapy
Panic Disorder
Photobiomodulation
Relaxation
TBI Treatment
Therapy